Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
124 hedge funds and large institutions have $1.81B invested in Blueprint Medicines in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 33 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 35
31% more capital invested
Capital invested by funds: $1.39B → $1.81B (+$426M)
7% less funds holding
Funds holding: 134 → 124 (-10)
12.06% less ownership
Funds ownership: 103.96% → 91.9% (-12%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
35% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $4.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$37.3M |
| 2 |
BlackRock
New York
|
+$34.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.8M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$23.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$49.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.2M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$22.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$21.7M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$13.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VSI
151
Verde Servicos Internacionais
Sao Paulo,
Brazil
| – | -$199K | -5,000 | Closed |
|
152
Simplex Trading
Chicago,
Illinois
| – | -$174K | -4,106 | Closed |
|
153
Group One Trading
Chicago,
Illinois
| – | -$111K | -2,781 | Closed |
|
|
PHK
154
Point72 Hong Kong
Hong Kong
| – | -$75K | -1,886 | Closed |
|
|
SCM
155
Segantii Capital Management
Hong Kong
| – | -$44K | -1,100 | Closed |
|
|
AIM
156
Acrospire Investment Management
Chicago,
Illinois
| – | -$26K | -648 | Closed |
|
|
CPIG
157
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$8K | -200 | Closed |
|
BPMC Hedge Fund Activity: Q2 2017 in Review
124 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2017, worth a combined $1.81B — up 31% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of BPMC and 23 opened new positions — a net loss of 10 holders — while 35 trimmed existing stakes and 54 added.
The largest buyer was OppenheimerFunds, adding an estimated $37.3M. The largest seller was Deerfield Management, cutting an estimated $49.3M.
- 124 institutional investors held Blueprint Medicines (BPMC) as of Q2 2017, down from 134 in Q1 2017.
- Funds reported $1.81B of Blueprint Medicines stock for Q2 2017, up 31% quarter-over-quarter.
- 23 funds opened new Blueprint Medicines positions in Q2 2017 and 33 closed out, a net change of -10 holders.
- The largest Blueprint Medicines buyer in Q2 2017 was OppenheimerFunds, an estimated $37.3M added.
- The largest Blueprint Medicines seller in Q2 2017 was Deerfield Management, an estimated $49.3M sold.
Based on aggregated 13F filings for Q2 2017.